Journal
BRITISH JOURNAL OF CANCER
Volume 114, Issue 1, Pages 59-62Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/bjc.2015.414
Keywords
biomarkers; metabolomics; screening; gastric cancer; nuclear magnetic resonance
Categories
Funding
- Edmonton Civic Employees Charitable Assistance Fund
- Alberta Innovates Technology Futures Graduate Student Scholarship
- Dr D Schiller Academic Enrichment Fund
- Queen Elizabeth II Graduate Scholarship
- Government of Canada
- Alberta Heritage Foundation for Medical Research (AHFMR) Population Health Investigator Award from Alberta Innovates Health Solutions (AIHS)
Ask authors/readers for more resources
Background: Metabolomics has shown promise in gastric cancer (GC) detection. This research sought to identify whether GC has a unique urinary metabolomic profile compared with benign gastric disease (BN) and healthy (HE) patients. Methods: Urine from 43 GC, 40 BN, and 40 matched HE patients was analysed using H-1 nuclear magnetic resonance (H-1-NMR) spectroscopy, generating 77 reproducible metabolites (QC-RSD <25%). Univariate and multivariate (MVA) statistics were employed. A parsimonious biomarker profile of GC vs HE was investigated using LASSO regularised logistic regression (LASSO-LR). Model performance was assessed using Receiver Operating Characteristic (ROC) curves. Results: GC displayed a clear discriminatory biomarker profile; the BN profile overlapped with GC and HE. LASSO-LR identified three discriminatory metabolites: 2-hydroxyisobutyrate, 3-indoxylsulfate, and alanine, which produced a discriminatory model with an area under the ROC of 0.95. Conclusions: GC patients have a distinct urinary metabolite profile. This study shows clinical potential for metabolic profiling for early GC diagnosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available